ArticleFrontiers in oncology2026
Case Report: Tislelizumab combined with bevacizumab in the treatment of primary malignant pericardial mesothelioma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary malignant pericardial mesothelioma (PMPM) is an exceedingly rare and highly malignant tumor that originates in the serosal layer of the pericardium. Currently, there are no specific guidelines for diagnosis and treatment in China and international countries for this disease, so treatment experiences from previous clinical cases are very important in the management of this disease. Case summary: A case involving grade IV bone marrow suppression following pemetrexed in combination with platinum-based chemotherapy has been documented. Subsequently, the patient underwent treatment with tislelizumab and bevacizumab (an immune checkpoint inhibitor combined with a vascular endothelial growth factor inhibitor). After 29.4 months of this treatment, the patient experienced significant relief from symptoms of chest tightness and breathlessness, while the primary tumor lesion remained stable. Imaging assessments indicated stable disease (SD). Throughout the treatment course, no severe adverse reactions resulting in mortality were observed, with only grade II bone marrow suppression and intermittent dry, scaly, and peeling skin on the feet reported. Symptoms improved following symptomatic and supportive interventions. Conclusion: This case report provides suggestive information for the application of tislelizumab combined with bevacizumab in the treatment of pericardial mesothelioma patients, especially those who are unable to tolerate the adverse effects associated with pemetrexed and platinum-based chemotherapy. The limitation is that only one patient is included, the number of cases is small, and there may be uniqueness of individual cases. Consequently, it remains uncertain whether this combination therapy is applicable to all patients with pericardial mesothelioma, nor can we ascertain whether other immune checkpoint inhibitor (ICIs) and vascular endothelial growth factor inhibitors (VEGF inhibitors) exhibit similar efficacy in this context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.